Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 108

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 4A
Chunk 108
---
 and will expire five years from issuance. The Series B Warrants have an exercise price of $3.55 per share, are
immediately exercisable upon issuance and will expire eighteen months from issuance. Our total gross proceeds from the 2024 Offering and
the Private Placement were approximately $5.5 million.

We also entered into a letter agreement dated August 23, 2024, or the Placement Agency Agreement, with
A. G. P./Alliance Global Partners, or AGP, as sole placement agent, pursuant to which AGP agreed to serve as the placement agent for us
in connection with the 2024 Offering. We paid AGP a cash placement fee equal to 7.0% of the gross proceeds received from the sale of the
securities sold in the 2024 Offering.

Lavie Bio Collaboration and SAFE with ICL

In August 2022, ICL and Lavie Bio entered a multi-year collaboration
agreement for developing novel bio-stimulant products to enrich fertilizer efficiency. As part of the collaboration, ICL invested (through
an affiliate company) in Lavie Bio $10 million under a SAFE (simple agreement for future equity). Information on that transaction is set
forth in this Annual Report under “ Item 4. Information on the Company - B. Business Overview - Market Segments - 
Agriculture - Lavie Bio Ltd. - Key Collaborations - ICL Group” and is incorporated by reference herein.

Biomica Share Purchase Agreement with SHC

On April 27, 2023, we announced the closing of a definitive
agreement for a $20 million financing round in Biomica, led by a $10 million investment from SHC, with an additional $10 million invested
by Evogene. Following the closing of this transaction, we hold approximately 67% of the share capital of Biomica, while SHC holds 20%,
in each case on a fully diluted basis. Information on that transaction is set forth in this Annual Report under “ Item 4. Information
on the Company - B. Business Overview - Market Segments - Human Health - Biomica Ltd. - Overview” and is
incorporated by reference herein.

68

Collaboration Agreements

Under our R& D collaboration agreements, our revenues typically
include R& D funding for activities that we conduct in the collaboration, as well as milestone payments for when the candidates advance
in our partners’ pipelines and revenue sharing from the end